Alto Neuroscience, Inc. (ANRO): רווח נקי למניה ב-12 החודשים האחרונים
The rolling net income per share trend for Alto Neuroscience, Inc. (ANRO) confirms a lack of profitability due to clinical trial costs for precision therapy. Revenues are based on investments in AI developments for treating psychiatric disorders, while consistent cash burn precludes positive FCF. Anticipation of Phase 2b depression results is impacting quotes, with the -2.48 metric determining this current yield level.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%A0%D7%A7%D7%99%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%90%D7%97%D7%AA%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_ANRO_-_Alto-Neuroscience-Inc._-_Net-earnings-per-one-share-for-the-last-twelve-months "רווח נקי למניה (EPS TTM) Alto Neuroscience, Inc. (ANRO): לתקופה 21.02.2024 - 15.11.2026 | 👁️GURU.Markets👁️")
פילוחים אנליטיים ודוחות נתונים של חברת Alto Neuro (ANRO)
This metric aggregates annual net income distributed across the total shares outstanding, reflecting the actual profitability per share after all expenses. For Alto Neuroscience, Inc. (ANRO), this figure is sensitive to biomarker research costs and partnerships with psychiatric centers. Investments in personalized therapy directly impact the bottom line. By analyzing the 12-month net income per share trend, investors assess the efficiency of capitalizing scientific developments.
